Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 2, 2002, Pages 111-116

  Cole, Peter D ^a   Smith, Angela K ^a   Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Ara A; Ara C; Drug resistance; Methotrexate; Osteosarcoma

Indexed keywords

CYTARABINE; DIPYRIDAMOLE; HYPOXANTHINE; METHOTREXATE; NUCLEIC ACID BASE; NUCLEOSIDE; NUCLEOSIDE DERIVATIVE; THYMIDINE; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIALYSIS; DRUG CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE METABOLISM; OSTEOSARCOMA; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; BONE NEOPLASMS; CATTLE; CULTURE MEDIA; CYTARABINE; DIALYSIS; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FETAL BLOOD; HUMANS; HYPOXANTHINE; METHOTREXATE; NEOPLASM PROTEINS; NUCLEOTIDES; OSTEOSARCOMA; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDINE; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0036353412     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0478-7     Document Type: Article

References (46)

1. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors
2. Cell killing studies on the mode of action of methotrexate on L-cells in vitro
3. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells
4. Cytidine analogs
5. Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity
6. Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance
7. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding
8. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
9. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein
10. Pharmacologic basis for the use of dipyridamole to increase the selectivity of intra-peritoneally delivered methotrexate
11. Mechanisms of methotrexate resistance in osteosarcoma
12. Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine
13. The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture
14. Oral dipyridamole and methotrexate in human solid tumors: A toxicity trial
15. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity
16. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate
17. Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport
18. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
19. Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo
20. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles
21. Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates
22. Cellular and clinical pharmacology of low-dose ara-C
23. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas
24. In vitro protein binding behavior of dipyridamole
25. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
26. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children
27. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study
28. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience
29. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
30. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
31. Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells
32. Potentiation of methotrexate toxicity by dipyridamole
33. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
34. The design of cancer chemotherapy: Metabolic modulation and cellular de novo versus salvage metabolism
35. Dipyridamole potentiates the growth-inhibitory action of methotrexate and 5-fluorouracil in human keratinocytes in vitro
36. Membrane transport and the antineoplastic action of nucleoside analogues
37. Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells
38. Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum
39. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
40. Fludarabine and high dose cytarabine (FLA): A well tolerated salvage regimen in acute myeloid leukaemia
41. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole
42. FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias
43. Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma
44. Salvage capacity of hepatoma 3924A and action of dipyridamole
45. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells
46. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans